Increased disease awareness and the IRA should help boost the RSV prevention market for older adults, said GSK CEO Emma Walmsley, ahead of a US approval decision early next month, as the firm’s vaccines division helped push a strong Q1 performance. Other deals are also ‘in the hopper.’
Better-than-expected performances from GSK plc’s vaccines, HIV and respiratory divisions helped get the firm off to a strong start in the first quarter, as it awaits approval of the first preventative vaccine for respiratory syncytial virus (RSV) and contemplates more bolt-on acquisitions and deals.
Having outperformed in 2022, the strong momentum for the UK major continued in the first quarter, with total sales of £6.95bn coming in above consensus of $6
Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.
Shares are hit as German conglomerate lowers revenue forecast.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
